Неантибактериальная терапия и профилактика острого и рецидивирующего цистита: существующие варианты и перспективы

Автор: Красняк Степан Сергеевич

Журнал: Экспериментальная и клиническая урология @ecuro

Рубрика: Инфекционно-воспалительные заболевания

Статья в выпуске: 1, 2020 года.

Бесплатный доступ

Введение. Инфекция мочевыводящих путей (ИМП) является одной из наиболее серьезных проблем общественного здравоохранения, затрагивающей оба пола, но женщины более восприимчивы к этому заболеванию из-за различий в урогенитальной и репродуктивной анатомии, физиологии и образе жизни. Материалы и методы. В статье рассмотены перспективные терапевтические стратегии для лечения и профилактики ИМП. С этой целью были изучены различные базы данных, в том числе Google Scholar, база данных Cochrane, PubMed и т. д. Поиск проводился по ключевым словам «профилактика», «рецидивирующие инфекции мочевых путей», «D-манноза», «проантоцианидины», «арбутин». Результаты и обсуждение. Представлены основные данные об этиологии, патогенезе, факторах риска, антибиотикотерапии и антибиотикопрофилактике ИМП. Показано, что микробные инфекционные агенты, включая Escherichia coli, Enterococcus faecalis и Klebsiella, являются основными возбудителяит ИМП. Антибиотики, такие как триметоприм-сульфаметоксазол, фторхинолоны, нитрофураны и т...

Еще

Профилактика, рецидивирующие инфекции мочевых путей, d-манноза, проантоцианидины, арбутин

Короткий адрес: https://sciup.org/142224037

IDR: 142224037   |   DOI: 10.29188/2222-8543-2020-12-1-136-143

Список литературы Неантибактериальная терапия и профилактика острого и рецидивирующего цистита: существующие варианты и перспективы

  • Nickel JC. Management of urinary tract infections: Historical perspective and current strategies: Part 1 - Before antibiotics. J Urol 2005;173: 21-6. DOI: 10.1097/01.ju.0000141496.59533.b2
  • Laupland KB, Ross T, Pitout JDD, Church DL, Gregson DB. Community-onset urinary tract infections: A population-based assessment. infection. 2007;35(3):150-3. DOI: 10.1007/s15010-007-6180-2
  • Ikahelmo R, Siitonen A, Heiskanen T, Karkkainen U, Kuosmanen P, Lipponen P, et al. Recurrence of Urinary Tract Infection in a Primary Care Setting: Analysis of a I-Year Follow-up of 179 Women. Clin Infect Dis 1996;22(1):91-9. DOI: 10.1093/clinids/22.1.91
  • Renard J, Ballarini S, Mascarenhas T, Zahran M, Quimper E, Choucair J, et al. Recurrent Lower Urinary Tract Infections Have a Detrimental Effect on Patient Quality of Life: a Prospective, Observational Study. Infect Dis Ther 2015;4(1): 125-35. DOI: 10.1007/s40121-014-0054-6
  • Foxman B. Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. Am J Med 2002; 113(1 SUPPL. 1):5-13. DOI: 10.1016/S0002-9343(02)01054-9
  • Fihn SD. Acute uncomplicated urinary tract infection in women. N Engl J Med 2003;349(3):259-66.
  • DOI: 10.1056/NEJMcp030027
  • Kodner CM, Thomas Gupton EK. Recurrent urinary tract infections in women: Diagnosis and management. Am Fam Physician. 2010;82(6):638-43.
  • Epp A, Larochelle A, Lovatsis D, Walter JE, Easton W, Farrell SA, et al. Recurrent Urinary Tract Infection. J Obstet Gynaecol Canada 2010;32(11): 1082-90.
  • DOI: 10.1016/S1701-2163(16)34717-X
  • Franco AVM. Recurrent urinary tract infections. Best Pract Res Clin Obstet Gynaecol 2005 Dec;19(6):861-73.
  • DOI: 10.1016/j.bpobgyn.2005.08.003
  • Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE. Risk Factors for Recurrent Urinary Tract Infection in Young Women. J Infect Dis 2000;182(4):1177-82.
  • DOI: 10.1086/315827
  • Hooton TM, Stapleton AE, Roberts PL, Winter C, Scholes D, Baven-dam T, et al. Perineal Anatomy and Urine-Voiding Characteristics of Young Women with and without Recurrent Urinary Tract Infections. Clin Infect Dis 1999;29(6):1600-1.
  • DOI: 10.1086/313528
  • Nseir W, Taha M, Nemarny H, Mograbi J. The association between serum levels of vitamin D and recurrent urinary tract infections in pre menopausal women. Int J Infect Dis 2013; 17( 12). 10.1016/ j.ijid.2013.06.007.
  • DOI: 10.1016/j.ijid.2013.06.007
  • Gupta K, Stapleton AE, Hooton TM, Roberts PL, Fennell CL, Stamm WE. Inverse Association of H2O2-Producing Lactobacilli and Vaginal Escherichia coli Colonization in Women with Recurrent Urinary Tract Infections. J Infect Dis 1998;178(2):446-50.
  • DOI: 10.1086/515635
  • Gupta K, Trautner BW. Diagnosis and management of recurrent urinary tract infections in non-pregnant women. BMJ (Online). 2013;346:f3140.
  • DOI: 10.1136/bmj.f3140
  • Albert X, Huertas I, Pereiro I, Sanfelix J, Gosalbes V, Perrotta C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev 2004;
  • DOI: 10.1002/14651858.cd001209.pub2
  • Beerepoot MAJ, Ter Riet G, Nys S, Van Der Wal WM, De Borgie CAJM, De Reijke TM, et al. Lactobacilli vs antibiotics to prevent urinary tract infections: A randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med 2012;172(9):704-12.
  • DOI: 10.1001/archinternmed.2012.777
  • Murray BE, Rensimer ER, Dupont HL. Emergence of High-Level Trimethoprim Resistance in Fecal Escherichia coli during Oral Administration of Trimethoprim or Trimethoprim-Sulfamethoxazole. N Engl J Med 1982;306(3):130-5.
  • DOI: 10.1056/NEJM198201213060302
  • Kahlmeter G. Cross-resistance and associated resistance in 2478 Escherichia coli isolates from the Pan-European ECO{middle dot} SENS Project surveying the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections. J Antimicrob Chemother 2003;52(1):128-31.
  • DOI: 10.1093/jac/dkg280
  • Kessel AS, Sharland M. The new UK antimicrobial resistance strategy and action plan: A major societal, political, clinical, and research challenge. BMJ 2013;346(7899).
  • DOI: 10.1136/bmj.f1601
  • Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52(5).
  • DOI: 10.1093/cid/ciq257
  • Health Protection Agency. Management of infection guidance for primary care for consultation & local adaption. Guidelines. 2014;(November):1-38.
  • Treatment of urinary tract infections in nonpregnant women. Obstet Gynecol 2008;111(3):785-94.
  • DOI: 10.1097/A0G.0b013e318169f6ef
  • Kontiokari T, Laitinen J, Jarvi L, Pokka T, Sundqvist K, Uhari M. Dietary factors protecting women from urinary tract infection. Am J Clin Nutr 2003;
  • DOI: 10.1093/ajcn/77.3.600
  • Hung CS, Bouckaert J, Hung D, Pinkner J, Widberg C, DeFusco A, et al. Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection. Mol Microbiol 2002;44(4):903-15.
  • DOI: 10.1046/j.1365-2958.2002.02915.x
  • Bouckaert J, Berglund J, Schembri M, De Genst E, Cools L, Wuhrer M, et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol Microbiol 2005;55(2):441-55.
  • DOI: 10.1111/j.1365-2958.2004.04415.x
  • Cusumano CK, Pinkner JS, Han Z, Greene SE, Ford BA, Crowley JR, et al. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med 2011;3( 109). 10.1126/ scitranslmed.3003021.
  • DOI: 10.1126/scitranslmed.3003021
  • Kranjcec B, Papes D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: A randomized clinical trial. World J Urol 2014;32(1):79-84.
  • DOI: 10.1007/s00345-013-1091-6
  • Urinary tract infection (recurrent): antimicrobial prescribing. [Internet]. 2018. URL: http://tinyurl.com/ya74guo6.
  • King SS, Young DA, Nequin LG, Carnevale EM. Use of specific sugars to inhibit bacterial adherence to equine endometrium in vitro. Am J Vet Res 2000;61(4):446-9.
  • DOI: 10.2460/ajvr.2000.61.446
  • Michaels EK, Chmiel JS, Plotkin BJ, Schaeffer AJ. Effect of D-man-nose and D-glucose on Escherichia coli bacteriuria in rats. Urol Res 1983; 11(2):97-102.
  • DOI: 10.1007/BF00256954
  • Porru D, Parmigiani A, Tinelli C, Barletta D, Choussos D, Di Franco C, et al. Oral D-mannose in recurrent urinary tract infections in women: A pilot study. J Clin Urol 2014;7(3):208-13.
  • DOI: 10.1177/2051415813518332
  • Domenici L, Monti M, Bracchi C, Giorgini M, Colagiovanni V, Muzii L, et al. D-mannose: a promising support for acute urinary tract infections in women. A pilot study. Eur Rev Med Pharmacol Sci [Internet]. 2016;20(13):2920-5. URL: http://www.ncbi.nlm.nih.gov/ pubmed/27424995.
  • Murray MT. Procyanidolic Oligomers. In: Textbook of Natural Medicine. 2013. p. 995-1000.
  • Scientific Opinion on the substantiation of a health claim related to CranMax* and reduction of the risk of urinary tract infection by inhibiting the adhesion of certain bacteria in the urinary tract pursuant to Article 14 of Regulation (EC) No 1924/2006. EFSA J. 2016;12(5):3657-68.
  • DOI: 10.2903/j.efsa.2014.3657
  • Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Sao Paulo Med J 2013;131 (5):363.
  • DOI: 10.1590/1516-3180.20131315T1
  • Cranberry (Vaccinii macrocarpi fructus). In: ESCOP Monographs: The scientific foundation for herbal medicinal products. New York: ESCOP (Exeter), Georg Thieme Verlarg (Stuttgart), Thieme New York; 2009. p. 255-69.
  • Beecher GR. Proanthocyanidins: Biological activities associated with human health. Pharm Biol. 2004;42(SUPPL.):2-20.
  • DOI: 10.1080/13880200490893474
  • Howell AB. Bioactive compounds in cranberries and their role in prevention of urinary tract infections. Mol Nutr Food Res. 2007 Jun;51(6):732-7.
  • DOI: 10.1002/mnfr.200700038
  • Li WG, Zhang XY, Wu YJ, Tian X. Anti-inflammatory effect and mechanism of proanthocyanidins from grape seeds. Acta Pharmacol Sin [Internet]. 2001;22(12):1117-20. URL: http://www.ncbi.nlm.nih.gov/ pubmed/11749811.
  • Bayeta E., Lau BHS. Pycnogenol inhibits generation of inflammatory mediators in macrophages. Nutr Res 2000;20(2):249-59.
  • DOI: 10.1016/S0271-5317(99)00157-8
  • Blazso G., Gabor M., Rohdewald P. Antiinflammatory activities of procyanidin-containing extracts from Pinus pinaster Ait. after oral and cutaneous application. Pharmazie 1997;52(5):380-2.
  • Chang WC, Hsu FL. Inhibition of platelet aggregation and arachi-donate metabolism in platelets by procyanidins. Prostaglandins, Leukot Essent Fat Acids 1989;38(3):181-8.
  • DOI: 10.1016/0952-3278(89)90070-7
  • Vadekeetil A., Alexandar V., Chhibber S., Harjai K. Adjuvant effect of cranberry proanthocyanidin active fraction on antivirulent property of ciprofloxacin against Pseudomonas aeruginosa. Microb Pathog 2016;
  • DOI: 10.1016/j.micpath.2015.11.024
  • Committee on herbal medicinal products (HMPC). Assessment report on Arctostaphylos uva-ursi (L.) Spreng., folium. European Medicines Agency. 2012.
  • Quintus J., Kovar KA, Link P., Hamacher H. Urinary excretion of arbutin metabolites after oral administration of bearberry leaf extracts. Planta Med 2005;71(2):147-52.
  • DOI: 10.1055/s-2005-837782
  • Maris P. Modes of action of disinfectants. Rev Sci Tech [Internet]. 1995;14(1):47-55. URL: http://www.ncbi.nlm.nih.gov/ pubmed/7548971.
  • De Arriba SG, Stammwitz U., Pickartz S., Coclik V., Bodinet C., Nolte KU. Anderungen des urin-pH-werts haben keinen einfluss auf die wirksamkeit von Uvae ursi folium. Zr Phytother 2010;31: 95-7.
  • DOI: 10.1055/s-0030-1247652
  • Geetha RV, Roy A., Lakshmi T. Nature's weapon against urinary tract infections [Internet]. International Journal of Drug Development and Research. 2011;3: 85-100. URL: http://www.embase.com/search/results?sub-action=viewrecord&from=export&id=L363060510
  • Rotblatt M. Herbal Medicine: Expanded Commission E. Monographs. Ann Intern Med 2013;133(6):487.
  • DOI: 10.7326/0003-4819-133-6-200009190-00031
  • Laurel K. Mydock-McGrane, Thomas J. Hannan & James W. Janetka Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease. Expert Opin Drug Discov 2017;12:7, 711-731,
  • DOI: 10.1080/17460441.2017.1331216
Еще
Статья научная